WST Cash & equivalents
Cash & equivalents at West Pharmaceutical Services rose to $791M in fiscal 2025, from $485M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 105770 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$791M
FY2024 $485M
HIGH$894M FY2022
LOW$485M FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $791M | +$307M |
| FY2024 | $485M | $-369M |
| FY2023 | $854M | $-40M |
| FY2022 | $894M | +$132M |
| FY2021 | $763M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · WST company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.